Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BYSTOLIC vs OPTIPRANOLOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bystolic (nebivolol) is a beta-1 selective adrenergic receptor antagonist with additional nitric oxide-mediated vasodilatory effects. It decreases heart rate, myocardial contractility, and blood pressure by blocking beta-1 receptors in the heart and kidney, and enhances nitric oxide release from vascular endothelium via beta-3 receptor activation.
Optipranolol is a non-selective beta-adrenergic receptor antagonist that blocks both beta-1 and beta-2 receptors. In the eye, it reduces intraocular pressure by decreasing aqueous humor production, likely via blockade of beta-2 receptors on the ciliary epithelium.
Hypertension: treatment of hypertension, alone or in combination with other antihypertensives,Heart failure: stable mild to moderate chronic heart failure in addition to standard therapy (off-label)
Treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma
Oral: 5 mg once daily; may increase at 2-week intervals to 10 mg, 20 mg, 40 mg; maximum 40 mg/day.
0.3% ophthalmic solution: Instill 1 drop into the affected eye(s) twice daily.
Terminal elimination half-life: 10-12 hours; allows once-daily dosing in most patients; steady-state achieved in 3-5 days
Terminal elimination half-life: 10-12 hours; allows twice-daily dosing in chronic use.
Extensively metabolized via CYP2D6 and glucuronidation. Active metabolites are formed, including desmethylnebivolol. Genetic polymorphisms in CYP2D6 affect drug levels.
Optipranolol undergoes extensive hepatic metabolism primarily via CYP2D6 and CYP1A2, with active metabolites including 4-hydroxyoptipranolol.
Renal: 38% unchanged; hepatic metabolism: extensive; fecal: minor; total renal clearance accounts for 30-50% of dose
Renal: 70% as unchanged drug and metabolites; biliary/fecal: 30%.
25-30% bound to albumin (alpha-1-acid glycoprotein not significant)
95% bound to albumin.
Vd: ~2.5 L/kg (extensive extravascular distribution, consistent with moderate lipophilicity)
1.5-2.5 L/kg, indicating extensive extravascular distribution.
Oral: 33% (due to first-pass metabolism; food does not significantly affect AUC; low variability)
Oral: 90% (high first-pass metabolism does not occur).
No adjustment for mild to moderate renal impairment (Cr Cl ≥30 m L/min). For severe renal impairment (Cr Cl <30 m L/min), initial dose 2.5 mg once daily; titrate cautiously; maximum 20 mg/day.
No dose adjustment required for systemic absorption; minimal systemic effect.
Child-Pugh Class A: initial 2.5 mg once daily; increase cautiously; maximum 20 mg/day. Child-Pugh Class B: initial 2.5 mg once daily; increase cautiously; maximum 10 mg/day. Child-Pugh Class C: not recommended.
No specific guidelines; use caution in severe hepatic impairment due to potential increased systemic exposure.
Not established; safety and efficacy not evaluated in pediatric patients.
Not established; safety and efficacy in pediatric patients have not been determined.
Initial dose 2.5 mg once daily; titrate slowly; maximum 40 mg/day. Monitor heart rate and blood pressure closely.
Monitor intraocular pressure and systemic effects; start at lowest effective dose.
No FDA black box warning.
None
Abrupt discontinuation may exacerbate angina or myocardial infarction in coronary artery disease,May mask signs of hyperthyroidism,Caution in peripheral vascular disease and Raynaud's phenomenon,May cause bronchospasm in patients with asthma or COPD,Caution in patients with diabetes mellitus due to masking of hypoglycemia,May cause bradycardia or heart block,Caution in renal or hepatic impairment
May exacerbate respiratory conditions such as asthma or COPD due to beta-2 blockade,May mask signs of hyperthyroidism and hypoglycemia,May precipitate heart failure or bradycardia in patients with pre-existing cardiac conditions,Use caution in patients with diabetes mellitus, as beta-blockers may blunt hypoglycemic symptoms,Abrupt withdrawal may exacerbate angina or precipitate myocardial infarction in patients with coronary artery disease
Sinus bradycardia,Second- or third-degree heart block,Cardiogenic shock,Decompensated heart failure,Sick sinus syndrome (unless pacemaker present),Severe hepatic impairment,Hypersensitivity to nebivolol or any component
Bronchial asthma,Severe chronic obstructive pulmonary disease,Sinus bradycardia,Second- or third-degree atrioventricular block,Cardiogenic shock,Overt cardiac failure,Hypersensitivity to optipranolol or any component
Avoid alcohol as it may increase blood pressure-lowering effect. No significant food interactions; however, grapefruit juice may slightly increase nebivolol levels but not clinically relevant.
Oral beta-blockers may interact with alcohol or high-tyramine foods, but topical optipranolol has minimal systemic absorption. No specific dietary restrictions are required for ophthalmic use.
First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimester: Beta-blockers may cause fetal bradycardia, intrauterine growth restriction, and neonatal hypoglycemia; risk is dose-dependent.
First trimester: Limited data; potential for embryo-fetal toxicity due to beta-blocker effects. Second and third trimesters: Possible intrauterine growth restriction (IUGR), neonatal bradycardia, hypoglycemia, and respiratory depression. Risk summary: Not recommended unless benefit outweighs risk.
Nebivolol is excreted into breast milk; M/P ratio not established. Limited human data; use with caution in nursing mothers due to potential for infant bradycardia and hypotension.
Metoprolol (active metabolite of optipranolol) excreted in breast milk; M/P ratio approximately 3.2. Monitor infant for bradycardia, hypotension, and hypoglycemia. Use with caution.
No specific dose adjustments established; use lowest effective dose; increase monitoring for maternal hypotension and fetal bradycardia; consider discontinuation if fetal distress occurs.
No specific dosing guidelines; increased plasma volume may require dose adjustment. Monitor clinical response; dose reduction may be needed due to enhanced drug clearance in later pregnancy. Gradual titration recommended.
Bystolic (nebivolol) is a beta-1 selective blocker with nitric oxide-mediated vasodilation, resulting in lower incidence of fatigue and sexual dysfunction compared to other beta-blockers. No dose adjustment needed in mild to moderate hepatic impairment but contraindicated in severe impairment. Maximum antihypertensive effect may take 2 weeks. Use caution in patients with asthma or COPD due to beta-1 selectivity may be lost at higher doses. Do not discontinue abruptly; taper over 1-2 weeks.
Optipranolol is a non-selective beta-blocker used topically for glaucoma. It reduces intraocular pressure by decreasing aqueous humor production. Caution in patients with bradycardia, heart block, or asthma due to systemic absorption. Monitor for systemic beta-blockade effects, especially in elderly or those with COPD. Contraindicated in sinus bradycardia, second- or third-degree AV block, cardiogenic shock, or hypersensitivity.
Take once daily at the same time each day, with or without food.,Do not stop taking suddenly as this may cause chest pain or heart attack; consult your doctor for gradual dose reduction.,May cause dizziness or drowsiness; avoid driving or operating machinery until you know how you react.,Notify your doctor if you experience slow heartbeat, shortness of breath, swelling of feet or legs, or signs of allergic reaction.,Inform all healthcare providers that you take this medication, especially before surgery or any procedure involving anesthesia.
Apply one drop to the affected eye(s) twice daily. Do not touch the dropper tip to any surface.,Remove contact lenses before instillation and wait at least 15 minutes before reinserting.,May cause temporary blurred vision. Avoid driving or operating machinery until vision clears.,Report symptoms of slow heart rate, difficulty breathing, or swelling of the hands/feet.,Use caution if you have asthma, COPD, diabetes, or thyroid disease due to potential systemic effects.,Do not discontinue abruptly; taper under medical supervision if stopping therapy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BYSTOLIC vs OPTIPRANOLOL, answered by our medical review team.
BYSTOLIC is a Beta Blocker that works by Bystolic (nebivolol) is a beta-1 selective adrenergic receptor antagonist with additional nitric oxide-mediated vasodilatory effects. It decreases heart rate, myocardial contractility, and blood pressure by blocking beta-1 receptors in the heart and kidney, and enhances nitric oxide release from vascular endothelium via beta-3 receptor activation.. OPTIPRANOLOL is a Beta Blocker (Ophthalmic) that works by Optipranolol is a non-selective beta-adrenergic receptor antagonist that blocks both beta-1 and beta-2 receptors. In the eye, it reduces intraocular pressure by decreasing aqueous humor production, likely via blockade of beta-2 receptors on the ciliary epithelium.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BYSTOLIC and OPTIPRANOLOL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BYSTOLIC is: Oral: 5 mg once daily; may increase at 2-week intervals to 10 mg, 20 mg, 40 mg; maximum 40 mg/day.. The standard adult dose of OPTIPRANOLOL is: 0.3% ophthalmic solution: Instill 1 drop into the affected eye(s) twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BYSTOLIC and OPTIPRANOLOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BYSTOLIC is classified as Category C. First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimester: Beta-blockers may cause fetal bradycardia, intraute. OPTIPRANOLOL is classified as Category C. First trimester: Limited data; potential for embryo-fetal toxicity due to beta-blocker effects. Second and third trimesters: Possible intrauterine growth restriction (IUGR), neonat. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.